Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP486381.RAHdX1mPlSTmwIj8y_TAOR6OpR1PUMh8AmZcXMmpM1GEQ130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP486381.RAHdX1mPlSTmwIj8y_TAOR6OpR1PUMh8AmZcXMmpM1GEQ130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP486381.RAHdX1mPlSTmwIj8y_TAOR6OpR1PUMh8AmZcXMmpM1GEQ130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP486381.RAHdX1mPlSTmwIj8y_TAOR6OpR1PUMh8AmZcXMmpM1GEQ130_provenance.
- NP486381.RAHdX1mPlSTmwIj8y_TAOR6OpR1PUMh8AmZcXMmpM1GEQ130_assertion description "[Imatinib mesylate (Gleevec, STI-571) is an inhibitor of ABL tyrosine kinase activity that has been remarkably effective in slowing disease progression in patients with chronic phase chronic myelogenous leukemia, but the emergence of imatinib resistance underscores the need for additional therapies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP486381.RAHdX1mPlSTmwIj8y_TAOR6OpR1PUMh8AmZcXMmpM1GEQ130_provenance.
- NP486381.RAHdX1mPlSTmwIj8y_TAOR6OpR1PUMh8AmZcXMmpM1GEQ130_assertion evidence source_evidence_literature NP486381.RAHdX1mPlSTmwIj8y_TAOR6OpR1PUMh8AmZcXMmpM1GEQ130_provenance.
- NP486381.RAHdX1mPlSTmwIj8y_TAOR6OpR1PUMh8AmZcXMmpM1GEQ130_assertion SIO_000772 15781610 NP486381.RAHdX1mPlSTmwIj8y_TAOR6OpR1PUMh8AmZcXMmpM1GEQ130_provenance.
- NP486381.RAHdX1mPlSTmwIj8y_TAOR6OpR1PUMh8AmZcXMmpM1GEQ130_assertion wasDerivedFrom befree-2016 NP486381.RAHdX1mPlSTmwIj8y_TAOR6OpR1PUMh8AmZcXMmpM1GEQ130_provenance.
- NP486381.RAHdX1mPlSTmwIj8y_TAOR6OpR1PUMh8AmZcXMmpM1GEQ130_assertion wasGeneratedBy ECO_0000203 NP486381.RAHdX1mPlSTmwIj8y_TAOR6OpR1PUMh8AmZcXMmpM1GEQ130_provenance.
- befree-2016 importedOn "2016-02-19" NP486381.RAHdX1mPlSTmwIj8y_TAOR6OpR1PUMh8AmZcXMmpM1GEQ130_provenance.